SUNNYVALE, Calif. and
ROTTERDAM, Netherlands, March 27,
2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ:
ARAY) and Erasmus MC, the largest university medical center in
the Netherlands, announced today
that the first patient has been successfully treated using an
online-adaptive (OA) approach together with the CyberKnife® System.
The patient, treated for oligometastases in the pelvic region, is
part of a new clinical trial conducted at Erasmus MC evaluating OA
stereotactic body radiation therapy (SBRT) delivered by the
CyberKnife platform. The trial brings the hospital one step closer
to its goal of providing individual, personalized medicine.
"At Erasmus MC our goal is to use innovative approaches to
provide customized, effective treatments that help extend or
improve the quality of life of people diagnosed with cancer,
regardless of the stage of their cancer diagnosis," said J.J.
Nuyttens, MD, PhD, radiation oncologist, department of radiation
oncology, Erasmus MC. "We initiated this trial because we want to
improve local cancer control and minimize toxicities in people with
pelvic or intra-abdominal oligometastases."
Oligometastastic disease occurs when cancer cells from the
primary tumor travel to other parts of the body and form a small
number (less than six) of lesions. The cancerous cells are in an
intermediate state; they are no longer confined to their initial
location nor have they spread widely throughout the body. Radiation
treatment of oligometastatic disease in the pelvic or
intra-abdominal area is challenging because of the close proximity
of healthy organs very sensitive to radiation. From one day to the
next there can be a significant variation in the position of these
organs and it can be difficult to account for the changes in their
location on a daily basis.
To address this issue, Accuray and Erasmus MC are partnering to
develop an integrated, advanced, imaging solution tailored for use
with the CyberKnife System. The purpose is to enable clinicians to
adapt the treatment plan to daily anatomical changes within the
patient. According to Dr. Nuyttens, "this OA-SBRT strategy provided
the treated patient with an optimal combination of dose to the
tumor and sparing of the surrounding healthy organs."
"We are thrilled to have the opportunity to collaborate with
Erasmus MC on the first step of a longer-term CyberKnife initiative
to enhance the quality of care clinicians can offer to their
patients," said Fabienne Hirigoyenberry-Lanson, PhD, Vice President
Global Medical and Scientific Affairs at Accuray. "We believe a
system that provides clinicians with the ability to tailor the
treatment on a daily basis through a fully automated solution, and
track and automatically correct for tumor or patient movement
throughout the treatment, has the potential to create a paradigm
shift in the way radiation is delivered and in cancer care."
About the Study
This study is a non-randomized single arm phase II clinical trial
evaluating the use of OA-SBRT for the treatment of oligometastatic
disease in the pelvic or paraaortic region. In total, 53 patients
will be enrolled and will be followed for three years. A
prescription dose of 45 Gy will be delivered in five fractions by
the CyberKnife System. The primary study objectives are to evaluate
local control, survival and toxicity.
Important Safety Information
For Important Safety Information please refer to
http://www.accuray.com/safety-statement.
About Erasmus MC Cancer Institute
Erasmus MC is committed to a healthy population and excellence in
healthcare through research and education. Professionals who are
trained by Erasmus MC unite the latest scientific insights with
practical application, so that patients and people with a
healthcare need can benefit fully from this link. Innovation and
state-of-the-art treatment go hand-in-hand at Erasmus MC.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative treatment
solutions that set the standard of care with the aim of helping
patients live longer, better lives. The company's leading-edge
technologies deliver the full range of radiation therapy and
radiosurgery treatments. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter
and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences and outcomes, and Accuray's
leadership position in radiation oncology innovation and
technologies. These forward-looking statements involve risks and
uncertainties. If any of these risks or uncertainties materialize,
or if any of the company's assumptions prove incorrect, actual
results could differ materially from the results expressed or
implied by these forward-looking statements. These risks and
uncertainties include, but are not limited to, the company's
ability to achieve widespread market acceptance of its products,
the company's ability to develop new products or enhance existing
products to meet customers' needs, the company's ability to
anticipate or keep pace with changes in the marketplace and the
direction of technological innovation and customer demands and such
other risks identified under the heading "Risk Factors" in the
company's annual report on Form 10-K, filed with the Securities and
Exchange Commission (the "SEC") on August
25, 2017, the company's quarterly report on Form 10-Q, filed
with the SEC on February 5, 2018 and
as updated periodically with the company's other filings with the
SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media
Contacts
|
|
Beth
Kaplan
|
Marisa
Borgasano
|
Public Relations
Director, Accuray
|
MSLGROUP
|
+1 (408)
789-4426
|
+1 (781)
684-0770
|
bkaplan@accuray.com
|
accuray@mslgroup.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/erasmus-mc-completes-first-step-in-the-evolution-of-online-adaptive-radiation-therapy-with-the-cyberknife-system-300619609.html
SOURCE Accuray Incorporated